NO20073059L - 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists - Google Patents

2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Info

Publication number: NO20073059L
Authority: NO; Norway
Prior art keywords: tetrahydro; carbazole derivatives; receptor antagonists; crth2 receptor; compounds
Prior art date: 2004-12-27

Application number

NO20073059A

Other languages

English (en)

Norwegian (no)

Inventor

Heinz Fretz

Anja Fecher

Markus Riederer

Original Assignee

Actelion Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-27

Filing date

2007-06-15

Publication date

2007-07-19

2007-06-15 Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd

2007-07-19 Publication of NO20073059L publication Critical patent/NO20073059L/no

Links

XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical class N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
102000009389 Prostaglandin D receptors Human genes 0.000 title 1
108050000258 Prostaglandin D receptors Proteins 0.000 title 1
239000002464 receptor antagonist Substances 0.000 title 1
229940044551 receptor antagonist Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
239000008194 pharmaceutical composition Substances 0.000 abstract 2
KPBVXYFKWJANIL-UHFFFAOYSA-N 2,3,4,4a-tetrahydro-1h-carbazole Chemical class C1=CC=C2C(CCCC3)C3=NC2=C1 KPBVXYFKWJANIL-UHFFFAOYSA-N 0.000 abstract 1
239000013543 active substance Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)

NO20073059A 2004-12-27 2007-06-15 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists NO20073059L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2004014719		2004-12-27
PCT/IB2005/054380 WO2006070325A2 (en)	2004-12-27	2005-12-22	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Publications (1)

Publication Number	Publication Date
NO20073059L true NO20073059L (no)	2007-07-19

Family

ID=36499938

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20073059A NO20073059L (no)	2004-12-27	2007-06-15	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists

Country Status (26)

Country	Link
US (1)	US8039474B2 (pl)
EP (1)	EP1833791B1 (pl)
JP (1)	JP5137240B2 (pl)
KR (1)	KR101329903B1 (pl)
CN (1)	CN101084190B (pl)
AR (1)	AR052549A1 (pl)
AT (1)	ATE518834T1 (pl)
AU (1)	AU2005320964B2 (pl)
BR (1)	BRPI0519280A2 (pl)
CA (1)	CA2594280C (pl)
CY (1)	CY1112376T1 (pl)
DK (1)	DK1833791T3 (pl)
ES (1)	ES2369782T3 (pl)
HR (1)	HRP20110773T1 (pl)
IL (1)	IL184233A0 (pl)
MX (1)	MX2007007691A (pl)
MY (1)	MY144897A (pl)
NO (1)	NO20073059L (pl)
NZ (1)	NZ556657A (pl)
PL (1)	PL1833791T3 (pl)
PT (1)	PT1833791E (pl)
RU (1)	RU2404163C2 (pl)
SI (1)	SI1833791T1 (pl)
TW (1)	TW200633978A (pl)
WO (1)	WO2006070325A2 (pl)
ZA (1)	ZA200705085B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
ATE530523T1 (de) *	2006-08-07	2011-11-15	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
BRPI0907364A2 (pt)	2008-02-01	2015-07-14	Amira Pharmaceuticals Inc	Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
JP2011513242A (ja)	2008-02-25	2011-04-28	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体アンタゴニスト
WO2010008864A2 (en)	2008-06-24	2010-01-21	Amira Pharmaceuticals, Inc.	Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors
GB2463788B (en)	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en)	2008-10-01	2010-04-08	Amira Pharmaceuticals, Inc.	Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en)	2008-10-08	2010-04-15	Amira Pharmaceuticals, Inc.	Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) *	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
CA2752981C (en) *	2009-02-24	2013-11-12	Merck Sharp & Dohme Corp.	Indole derivatives as crth2 receptor antagonists
EP2461809A4 (en)	2009-07-31	2013-06-19	Panmira Pharmaceuticals Llc	OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
US8815917B2 (en)	2009-08-05	2014-08-26	Panmira Pharmaceuticals, Llc	DP2 antagonist and uses thereof
AR080703A1 (es)	2010-03-22	2012-05-02	Actelion Pharmaceuticals Ltd	Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
EP2627178B1 (en)	2010-10-11	2018-05-02	Merck Sharp & Dohme Corp.	Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (en)	2010-11-25	2012-05-30	Almirall, S.A.	New pyrazole derivatives having CRTh2 antagonistic behaviour
DK2697223T3 (en)	2011-04-14	2016-09-05	Actelion Pharmaceuticals Ltd	7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
US20140128367A1 (en) *	2011-06-17	2014-05-08	Merck Sharp & Dohme Corp.	Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
PE20161177A1 (es)	2014-03-17	2016-11-18	Actelion Pharmaceuticals Ltd	Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (en)	2014-03-18	2015-09-24	Actelion Pharmaceuticals Ltd	Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
KR20180053345A (ko)	2015-09-15	2018-05-21	이도르시아 파마슈티컬스 리미티드	결정질 형태
CN117143007B (zh) *	2023-08-31	2026-01-09	陕西科技大学	一种四氢咔唑衍生物及其光催化合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE376235B (pl) *	1970-06-02	1975-05-12	Sterling Drug Inc
US3687969A (en) *	1970-06-02	1972-08-29	Sterling Drug Inc	9-aroyl-1,2,3,4-tetrahydrocarbazole-3,3-dicarboxylic acids
US3941805A (en) *	1972-11-17	1976-03-02	Sterling Drug Inc.	3-Halomethylcarbonyl-9-benzoyl-1,2,3,4-tetrahydrocarbazoles
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
CA2106642C (en) *	1992-10-14	2005-08-16	Peter Bod	Carbazolone derivatives and process for preparing the same
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
AU2002302248B2 (en)	2001-05-23	2008-03-06	Merck Frosst Canada Ltd.	Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
WO2003051837A2 (de) *	2001-12-14	2003-06-26	Zentaris Gmbh	Tetrahydrocarbazolderivate als liganden für g-protein gekoppelte rezeptoren (gpcr)
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200356D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
SE0200411D0 (sv)	2002-02-05	2002-02-05	Astrazeneca Ab	Novel use
AU2003231509A1 (en)	2002-05-16	2003-12-02	Shionogi And Co., Ltd.	Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (en)	2002-05-16	2003-11-27	Shionogi & Co., Ltd.	Pgd2 receptor antagonist
GB2388540A (en) *	2002-05-17	2003-11-19	Bayer Ag	New use of Ramatroban
TW200307542A (en)	2002-05-30	2003-12-16	Astrazeneca Ab	Novel compounds
SE0201635D0 (sv)	2002-05-30	2002-05-30	Astrazeneca Ab	Novel compounds
SE0202241D0 (sv)	2002-07-17	2002-07-17	Astrazeneca Ab	Novel Compounds
WO2004039807A1 (en)	2002-10-30	2004-05-13	Merck Frosst Canada & Co.	Pyridopyrrolizine and pyridoindolizine derivatives
JPWO2004078719A1 (ja)	2003-03-06	2006-06-08	小野薬品工業株式会社	インドール誘導体化合物およびその化合物を有効成分とする薬剤
US20070054951A1 (en)	2003-05-20	2007-03-08	Lianhai Li	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv)	2003-05-27	2003-05-27	Astrazeneca Ab	Novel compounds
WO2004111047A2 (en)	2003-06-12	2004-12-23	Merck Frosst Canada Ltd.	Cycloalkanepyrrolopyridines as dp receptor antagonists
SE0302232D0 (sv)	2003-08-18	2003-08-18	Astrazeneca Ab	Novel Compounds
WO2005040112A1 (en)	2003-10-14	2005-05-06	Oxagen Limited	Compounds with pgd2 antagonist activity
US20070232681A1 (en)	2003-10-14	2007-10-04	Oxagen Limited	Compounds Having Crth2 Antagonist Activity
GB2407318A (en)	2003-10-23	2005-04-27	Oxagen Ltd	Substituted Indol-3-yl acetic acid derivatives
GB0324763D0 (en)	2003-10-23	2003-11-26	Oxagen Ltd	Use of compounds in therapy
SE0303180D0 (sv)	2003-11-26	2003-11-26	Astrazeneca Ab	Novel compounds
US7019022B2 (en)	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN100584844C (zh)	2004-01-31	2010-01-27	艾克提麦斯医药品有限公司	咪唑[1,2-c]嘧啶基乙酸衍生物
US7714132B2 (en)	2004-03-11	2010-05-11	Actelion Pharmaceuticals, Ltd.	Tetrahydropyridoindole derivatives
JP4861976B2 (ja)	2004-03-11	2012-01-25	アクテリオンファーマシューティカルズリミテッド	インドール−１−イル酢酸誘導体
KR101213912B1 (ko)	2004-08-26	2012-12-18	액테리온 파마슈티칼 리미티드	Ｃｒｔｈ2 길항제로서의2-설파닐-벤조이미다졸-1-일-아세틱 애시드 유도체
ATE530523T1 (de)	2006-08-07	2011-11-15	Actelion Pharmaceuticals Ltd	(3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate

2005
- 2005-12-22 CA CA2594280A patent/CA2594280C/en not_active Expired - Fee Related
- 2005-12-22 BR BRPI0519280-3A patent/BRPI0519280A2/pt not_active IP Right Cessation
- 2005-12-22 NZ NZ556657A patent/NZ556657A/en not_active IP Right Cessation
- 2005-12-22 ES ES05850906T patent/ES2369782T3/es not_active Expired - Lifetime
- 2005-12-22 JP JP2007547781A patent/JP5137240B2/ja not_active Expired - Fee Related
- 2005-12-22 DK DK05850906.8T patent/DK1833791T3/da active
- 2005-12-22 CN CN2005800438848A patent/CN101084190B/zh not_active Expired - Fee Related
- 2005-12-22 HR HR20110773T patent/HRP20110773T1/hr unknown
- 2005-12-22 AU AU2005320964A patent/AU2005320964B2/en not_active Ceased
- 2005-12-22 RU RU2007128736/04A patent/RU2404163C2/ru not_active IP Right Cessation
- 2005-12-22 KR KR1020077017341A patent/KR101329903B1/ko not_active Expired - Fee Related
- 2005-12-22 PL PL05850906T patent/PL1833791T3/pl unknown
- 2005-12-22 WO PCT/IB2005/054380 patent/WO2006070325A2/en not_active Ceased
- 2005-12-22 MX MX2007007691A patent/MX2007007691A/es active IP Right Grant
- 2005-12-22 PT PT05850906T patent/PT1833791E/pt unknown
- 2005-12-22 SI SI200531395T patent/SI1833791T1/sl unknown
- 2005-12-22 EP EP05850906A patent/EP1833791B1/en not_active Expired - Lifetime
- 2005-12-22 AT AT05850906T patent/ATE518834T1/de active
- 2005-12-22 US US11/722,095 patent/US8039474B2/en not_active Expired - Fee Related
- 2005-12-23 MY MYPI20056197A patent/MY144897A/en unknown
- 2005-12-26 TW TW094146581A patent/TW200633978A/zh unknown
- 2005-12-27 AR ARP050105557A patent/AR052549A1/es not_active Application Discontinuation
2007
- 2007-06-13 ZA ZA200705085A patent/ZA200705085B/xx unknown
- 2007-06-15 NO NO20073059A patent/NO20073059L/no not_active Application Discontinuation
- 2007-06-26 IL IL184233A patent/IL184233A0/en not_active IP Right Cessation
2011
- 2011-11-02 CY CY20111101047T patent/CY1112376T1/el unknown

Also Published As

Publication number	Publication date
CN101084190A (zh)	2007-12-05
ZA200705085B (en)	2008-08-27
KR20070104367A (ko)	2007-10-25
RU2404163C2 (ru)	2010-11-20
AR052549A1 (es)	2007-03-21
BRPI0519280A2 (pt)	2009-01-06
CA2594280A1 (en)	2006-07-06
JP2008525426A (ja)	2008-07-17
MY144897A (en)	2011-11-30
IL184233A0 (en)	2007-10-31
HRP20110773T1 (hr)	2011-11-30
ES2369782T3 (es)	2011-12-05
CA2594280C (en)	2013-04-23
EP1833791A2 (en)	2007-09-19
ATE518834T1 (de)	2011-08-15
TW200633978A (en)	2006-10-01
PL1833791T3 (pl)	2011-12-30
AU2005320964A1 (en)	2006-07-06
KR101329903B1 (ko)	2013-11-14
CY1112376T1 (el)	2015-12-09
US8039474B2 (en)	2011-10-18
SI1833791T1 (sl)	2011-11-30
EP1833791B1 (en)	2011-08-03
RU2007128736A (ru)	2009-02-10
AU2005320964B2 (en)	2011-12-15
WO2006070325A3 (en)	2006-09-14
WO2006070325A2 (en)	2006-07-06
HK1111698A1 (en)	2008-08-15
CN101084190B (zh)	2011-01-26
MX2007007691A (es)	2007-08-14
PT1833791E (pt)	2011-10-19
JP5137240B2 (ja)	2013-02-06
US20090270414A1 (en)	2009-10-29
NZ556657A (en)	2010-10-29
DK1833791T3 (da)	2011-10-24

Legal Events

Date	Code	Title	Description
2014-07-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20073059L (no)	2007-07-19	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
NO20064347L (no)	2006-09-26	Substituerte 1,2,3,4-tetrahydroisokinolinderivater
NO20064584L (no)	2006-10-10	Tetrahydropyridoindolderivater
ATE470443T1 (de)	2010-06-15	Indol-1-yl-essigsäurederivate
WO2007149406A3 (en)	2008-07-10	Modified coagulation factor ix polypeptides and use thereof for treatment
NO20072322L (no)	2007-07-19	Laktamforbindelser og anvendelse derav som farmasoytiske midler
NO20070372L (no)	2007-03-08	Amidoforbindelser og anvendelse derav som farmasoytiske preparater
NO20071048L (no)	2007-05-08	Amidoforbindelser og deres anvendelse som farmasoytika
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
ATE496884T1 (de)	2011-02-15	Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
NO20082269L (no)	2008-05-20	Nye piperaziner som antimalariamidler
NO20073876L (no)	2007-09-10	Pyrazolopyrimidinderivater som mGluR2-antagonister
IL184898A0 (en)	2007-12-03	Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20092529L (no)	2009-08-27	Substituerte 2,3-dihydroimidazo[1,2-c]kinazolinderivater som er anvendbare for behandling av hyperproliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20072352L (no)	2007-05-31	Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20042844L (no)	2004-08-23	4-(piperidyl- og pyrrolidyl-alkyl-ureido)-kinoliner som uprotensin II reseptor-antagonister
NO20060978L (no)	2006-05-26	Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
NO20070487L (no)	2007-03-05	3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
CY1108794T1 (el)	2014-04-09	Σπειροκυκλικα παραγωγα κυκλοεξανιου
NO20100301L (no)	2010-03-25	Forbedrete brimonidinsammensetninger for behandling av erytem
NO20050932L (no)	2005-04-15	1-pyridin-4-yl-ureaderivater
DK1654253T3 (da)	2007-04-30	Substituerede 3-pyrrolidinindolderivater
NO20083905L (no)	2008-09-12	Nye pyron-indol derivater og fremgangsmate for deres fremstilling
CY1109537T1 (el)	2014-08-13	Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
NO20092073L (no)	2009-06-26	Modulatorer av C3A-reseptor, og fremgangsmater for anvendelse derav